
Megan McGill, M.D., Ph.D., is the chief executive officer and a board member of Brenig Therapeutics, a clinical-stage neuroscience biotech using an AI-based discovery platform to build small-molecule treatments for neurodegenerative disease. She took the role on October 30, 2025, to steer Brenig's lead Parkinson's program, the LRRK2 inhibitor BT-267, through early human trials. Trained in MRI physics and neuroimaging at NYU and in radiology at Memorial Sloan Kettering, she traded the reading room for the boardroom, building a decade-long run that spans McKinsey consulting, business development at BridgeBio and Regenxbio, and the CEO seat at Epitor, Regel, and HitchBio.
Neural Galaxy (also operating as Galaxy Brain Scientific) is a Beijing-based brain science company building a precision, non-invasive neuromodulation platform. Its proprietary personalized Brain Functional Sectors (pBFS) technology maps over 200 functional regions of an individual brain, then guides targeted transcranial magnetic stimulation with millimeter accuracy. Founded in 2019 by Harvard and MIT neuroscientists with serial entrepreneur Coach Wei, the company is running clinical and registration trials across depression, Parkinson's, Alzheimer's, autism and aphasia, and has raised roughly $93M to date.